In a significant development for branded pharmaceutical patent protection, Intra-Cellular Therapies, Inc. filed a patent infringement action against Sandoz, Inc. in the U.S. District Court for New Jersey on March 28, 2024, asserting 16 patents covering its blockbuster psychiatric drug CAPLYTA® (lumateperone). The case, docketed as 3:24-cv-04264, was resolved procedurally on August 5, 2024 — just 130 days after filing — when the court ordered it consolidated into a lead ANDA proceeding, Civil Action No. 3:24-cv-04264, alongside other related actions targeting generic challengers to the lumateperone franchise.

This consolidation is strategically important for both branded drug IP holders and generic entrants navigating the Hatch-Waxman ANDA litigation landscape. With 16 patents in suit spanning lumateperone’s chemistry, formulation, dosing regimens, and 5-HT2A receptor activity, the outcome of the lead consolidated case will carry sweeping consequences for market exclusivity. Patent attorneys, in-house IP teams at pharmaceutical companies, and R&D leaders developing CNS therapeutics should closely monitor the consolidated proceedings for claim construction rulings and validity challenges.

Case Overview

The Parties

The Patents at Issue

The 16 patents asserted in this case collectively cover lumateperone (CAPLYTA®), a novel atypical antipsychotic that works through simultaneous modulation of serotonin 5-HT2A receptors, dopamine, and glutamate pathways. The patents span foundational compound chemistry (e.g., US9199995B2, US8648077B2), specific dosage forms and capsule formulations (US10464938B2, US11026951B2), methods of treating psychiatric conditions including schizophrenia and bipolar depression, and reissue patents covering refined therapeutic applications (USRE048839E, USRE048825E). Together, they form a layered patent thicket designed to protect lumateperone from all angles of generic challenge, from the molecule itself to the clinical dosing regimens.

• • US11026951B2
• • US10464938B2
• • US9168258B2
• • US10960009B2
• • US9956227B2
• • US9616061B2
• • US9199995B2
• • US11806348B2
• • USRE048839E
• • US10695345B2
• • USRE048825E
• • US11690842B2
• • US11753419B2
• • US10117867B2
• • US8648077B2
• • US11052084B2

Legal Representation

Plaintiff Counsel: Walsh Pizzi O’Reilly Falanga LLP (lead: Katelyn O’Reilly)
Defendant Counsel: Hill Wallack, LLP (lead: Eric I. Abraham)

Litigation Timeline & Procedural History

This case was filed in the U.S. District Court for the District of New Jersey on March 28, 2024 — a venue well-established as a premier forum for Hatch-Waxman ANDA litigation given its experienced judiciary, dense pharmaceutical industry presence, and procedural familiarity with complex multi-patent drug cases. As a first-instance district court proceeding, this action represents the initial trial-level forum where infringement, validity, and enforceability of the asserted patents would ordinarily be adjudicated, with any appeal directed to the U.S. Court of Appeals for the Federal Circuit.

The case closed in just 130 days — a swift resolution that reflects not a merits determination but a procedural consolidation. On August 5, 2024, the court ordered Civil Action No. 3:24-cv-04327 merged into the lead consolidated case, Civil Action No. 3:24-cv-04264, which encompasses multiple parallel ANDA actions filed by various generic challengers against CAPLYTA®’s patent estate. All pro hac vice admissions from this and other consolidated actions were carried over into the lead case, streamlining counsel participation. No damages, injunctions, or validity rulings were issued in this action — all substantive determinations now belong to the consolidated proceeding.

The Verdict & Legal Analysis

Outcome

Case No. 3:24-cv-04327 was closed on August 5, 2024 via consolidation into lead Civil Action No. 3:24-cv-04264, with the court ordering all future filings to proceed under the lead docket number. No merits ruling on infringement or patent validity was issued in this action, and no damages, injunctive relief, or cost allocation was determined. All attorneys admitted pro hac vice in the consolidated actions, including this case, were deemed admitted in the lead proceeding.

Verdict Cause Analysis

The basis of termination — case consolidation — reflects a common judicial management approach in Hatch-Waxman ANDA litigation where multiple generic filers challenge the same branded drug’s patent estate simultaneously.

• Intra-Cellular Therapies filed parallel ANDA infringement suits against multiple generic challengers of CAPLYTA® (lumateperone), including Sandoz, resulting in several related cases pending before the New Jersey District Court.
• The court exercised its discretion under Federal Rule of Civil Procedure 42(a) to consolidate Civil Action No. 3:24-cv-04327 into the lead case, Civil Action No. 3:24-cv-04264, to avoid duplicative discovery, claim construction proceedings, and potentially inconsistent rulings across the co-pending actions.
• Pro hac vice admissions from all consolidated actions were expressly carried over to the lead proceeding, ensuring continuity of legal representation and reducing administrative burden on both counsel and the court.
• No substantive findings on infringement, validity, or enforceability of any of the 16 asserted patents were made in this action prior to consolidation, leaving all merits issues to be resolved in the lead consolidated case.

Legal Significance

1. The consolidation of multiple ANDA suits targeting the same branded drug into a lead proceeding is a well-established judicial efficiency mechanism, but it concentrates enormous patent validity and claim construction risk into a single proceeding — a loss on any claim in the lead case can bind all consolidated defendants.
2. With 16 patents asserted — including two reissue patents (USRE048839E and USRE048825E) — this consolidated litigation will likely generate significant Federal Circuit precedent on the scope of reissue patent broadening recapture and the patentability of continuation-based formulation claims in the CNS drug space.
3. The layered portfolio strategy employed by Intra-Cellular, combining compound, formulation, dosing method, and reissue patents across more than a decade of prosecution, exemplifies a best-practice approach to building durable Hatch-Waxman litigation exclusivity that competitors and their IP counsel should study carefully.

Strategic Takeaways

For Patent Attorneys:

• When representing branded pharmaceutical clients, pursue consolidation of parallel ANDA actions early and aggressively — concentrating cases into a single lead proceeding allows coordinated claim construction strategy and reduces the risk of inconsistent rulings that could be exploited by generic challengers.
• The inclusion of reissue patents (USRE048839E, USRE048825E) alongside original patents in a 16-patent assertion signals that prosecution-level recapture and broadening strategies are actively being used to shore up IP protection; attorneys prosecuting CNS drug portfolios should consider reissue filings as a standard lifecycle tool.
• Pro hac vice admission orders in consolidated ANDA cases should be carefully reviewed to ensure all relevant counsel are explicitly captured — the court’s order here extending prior admissions into the lead case is procedurally clean but requires proactive monitoring by lead counsel.
• When drafting ANDA paragraph IV certifications or responding to them, assess the entire continuation chain and reissue history of the patent family — Intra-Cellular’s portfolio spans application numbers from US12/922056 through US17/757212, reflecting over a decade of layered prosecution that must be fully mapped before any invalidity or design-around strategy is formulated.

For IP Professionals:

• In-house IP teams at branded pharmaceutical companies should benchmark Intra-Cellular’s 16-patent CAPLYTA® portfolio strategy — spanning compound, formulation, dosage, method-of-treatment, and reissue patents — as a model for building multi-layered Hatch-Waxman protection across a drug’s full commercial lifecycle.
• Monitor the consolidated lead case, Civil Action No. 3:24-cv-04264, for claim construction orders and any IPR petitions filed by Sandoz or co-defendants against the asserted patents, as outcomes there will directly affect the FTO landscape for any lumateperone-adjacent CNS drug programs in your pipeline.

For R&D Teams:

• R&D teams developing generic or follow-on CNS therapies targeting 5-HT2A receptor modulation must conduct thorough FTO analyses against all 16 asserted patents — particularly the method-of-treatment and dosing regimen claims — before committing to formulation or clinical development pathways that overlap with lumateperone’s therapeutic profile.
• The breadth of Intra-Cellular’s patent coverage, from the core lumateperone compound to specific capsule strengths (10.5 mg, 21 mg, 42 mg), means that conventional formulation design-arounds may be insufficient; R&D teams should explore differentiated receptor-binding profiles, delivery mechanisms, or combination approaches that fall outside the asserted claim scope.